Biotech, Partnering

Neurotez signs licensing deal for Leptin

Posted on 27 May 2014

Tags: , ,

Neurotez announced the execution of an exclusive license agreement covering its Leptin derivatives (Leptin Products), for the treatment of Alzheimer’s disease (AD) and other cognitive disorders, with GCA Therapeutics.

The exclusive license grants GCAT the right to clinically develop and commercialize Leptin Products in mainland China, exclusive of Hong Kong, and Taiwan.

A version of Leptin has recently been approved in the USA for treating generalized lipodystrophy and in Japan for lipodystrophy.

GCAT will assume all development and regulatory responsibility and associated costs for Leptin Products in China, and Neurotez will be eligible to receive gross sales milestones up to US$102.5 million as well as royalties on gross sales.

The exclusive license also has certain minimum annual sales thresholds following first commercial sales in mainland China.

For further deal information visit Current Agreements (subscription required)


Browse: Complete Current Partnering report catalog

View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value

View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making

View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity

View: Current Partnering’s Big Biotech Deal Making Scorecard – latest trends in big biotech deal making activity

Signup: Current Partnering Dealmakers Update – weekly newsletter providing the latest life science industry deal news, deal making trends, partnering events – sign up now

Signup: Current Agreements Deals Review – monthly newsletter – reviewing the previous month’s life science deal making – partnering, M&A and financing – sign up now

Subscribe: Current Agreements life sciences partnering, M&A and financing deals database – find out more

Follow us on: LinkedIn Current Partnering | LinkedIn Business Development Network | @Currentpartner on Twitter

Print Friendly, PDF & Email

Leave a Reply